浙江鼎辉医药科技

Dinghui Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs. The company's research focus encompasses metabolic diseases, oncology, and inflammatory disorders, with a particular emphasis on addressing unmet needs in liver health. Its lead program, DH001, is a potent and selective thyroid hormone receptor beta (THR-beta) agonist designed to treat non-alcoholic steatohepatitis (NASH). By utilizing its internal drug discovery capabilities, Dinghui aims to create therapies with superior safety and efficacy profiles compared to existing standards of care. The company has successfully secured significant venture capital funding to advance its pipeline through global clinical trials.